In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with TJ Higley, CEO at Microsize.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with TJ, covering:
The fast, easy, scalable, precise, and non-patent-protected benefits of micronization
How a synergistic capability alliance led to the eventual sale of his business to Lonza Capsugel
The risks and realities of being an entrepreneur acquiring an organization, and then the collective rewards by incentivizing a team
How a ‘getting the band back together’ call led to TJ taking back the site he once sold to create Microsize
The importance of strategic partnerships and recognizing that you can’t do everything yourself
TJ joined Microsize in 2022 as CEO to lead the company into the next growth phase. TJ brings 25 years of experience in the pharmaceutical market, most uniquely as a former owner and executive leader of Powdersize, Inc., the original and first CMO focused on pharmaceutical micronization in the US. TJ led both the business development efforts and oversaw the site quality team during his tenure, culminating in the acquisition of the company by Capsugel in 2015 and the integration into Lonza in 2017.
Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.
The servant leader creating the next generation CDMO